Bolt Technology Corp

Bolt Biotherapeutics Inc. a clinical-stage biotechnology company engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001 which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors including breast colorectal endometrial and gastroesophageal cancer. It is also developing BDC-2034 an agonist antibody targeting Dectin-2 for range of tumors such as head and neck non-small cell lung ovarian triple-negative breast and other cancer. The company has collaboration agreements with Toray Industries Genmab A/S Innovent Biologics Inc. Bristol-Myers Squibb and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics Inc. and changed its name to Bolt Biotherapeutics Inc. in July 2015. Bolt Biotherapeutics Inc. was incorporated in 2015 and is headquartered in Redwood City California.